Ten Bokkel HuinikW., GoreM., CarmichaelJ.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol., 15: 2183–2193, 1997.
2.
ArdizzoniA., HansenH., DombernowskyP.: Topotecan, a new active drug in the second-line treatment of small cell lung cancer: a phase II study in patients with refractory and sensitive disease. J. Clin. Oncol., 15: 2090–2096, 1997.
3.
Ten Bokkel HuinikW., GoreM., CarmichaelJ.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol., 15: 2183–2193, 1997.
4.
ArdizzoniA., HansenH., DombernowskyP.: Topotecan, a new active drug in the second-line treatment of small cell lung cancer: a phase II study in patients with refractory and sensitive disease. J. Clin. Oncol., 15: 2090–2096, 1997.
5.
RowinskyE.K., GrochowL.B., HendricksC.B.: Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647–656, 1992.
6.
GerritsC.J., BurrisH., SchellensJ.H.: Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clin. Cancer Res., 4: 1153–1158, 1998.
7.
MillerA.A., LillenbaumR.C., HollisR.C.: Pharmacologic study of continuous infusion topotecan and cisplatin in patients with advanced cancer. A Cancer and Leukemia Group B study. J. Clin. Oncol., 12: 2743–2750, 1994.
8.
RowinskyE.K., KaufmannS.H., GrochowL.B.: Sequences of topotecan and cisplatin: Phase I, pharmacologic and in vitro studies examining sequence-dependence. J. Clin. Oncol., 14: 3074–3084, 1996.
9.
LilenbaumR. C., RatainM.J., MillerA.A.: Phase I study of paclitaxel and topotecan in patients with advanced tumors. A Cancer Leukemia Group B study. J. Clin. Oncol., 13: 2230–2237, 1995.
10.
HochsterH., SpeyerJ., OratzR.: Phase I study of taxol with 14-day topotecan continuous low-dose infusion. Proc. Am. Soc. Clin. Oncol., 14: 486, 1995.
11.
O'ReillyS., BakerS., FedeleJ.: Phase I and pharmacologic trial of sequences of paclitaxel and topotecan in patients with advanced ovarian epithelial malignancies: a gynecologic oncology group study. J. Clin. Oncol., 15: 177–186, 1997.
12.
MurrenJ.R., AndersonS., FedeleJ.: Dose escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. J. Clin. Oncol., 15: 148–157, 1997.
13.
CrumpM., LiptonJ., HedleyD.: Phase I trial of sequential topotecan and etoposide in adult acute myeloid leukemia. Blood, 88(Suppl 1): 867, 1996.
14.
de JongeM.J.A., SparreboomA., PlantingA.S.: Sequence-dependent side effects of oral topotecan with intravenous cisplatin in a phase I and pharmacological study in patients with advanced solid tumors. Proc. Am. Soc. Clin. Onc., 17: A784, 1998.
15.
HeidemanR., KuttesckJ., StewartC.: A phase I trial of a fixed systemic exposure of carboplatin with continuous infusion topotecan in pediatric solid tumors. Proc. Am. Soc. Clin. Oncol., 14: A447, 1995.
16.
TolcherA.W., O'ShaughnessyJ.A., WeissR.B.: Phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancy. Clin. Cancer Res., 3: 755–760, 1997.
17.
HoskinsP., EisenhauerE., BeareS.: et al. Randomised phase II study of two schedule of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol., 16: 2233–2237, 1998.
18.
GordonA., CarmichaelE., MalfetanoJ.: Final analysis of a phase III randomised study of topotecan vs paclitaxel in advanced epithelial ovarian carcinoma: international topotecan study group. Proc. Am. Soc. Clin. Onc., 17: A1374, 1998.
19.
GoreM., RustinG., CalvertH.: A multicentre randomised phase III study of topotecan administered intravenously or orally for advanced epithelial ovarian carcinoma. Proc. Am. Soc. Clin. Onc., 17: A1346, 1998.
20.
Perez SolerR., KhuriF., PistersK.M.: Phase II study of topotecan in patients with squamous carcinoma of the lung previously untreated with chemotherapy. Proc. Am. Soc. Clin. Onc., 17: A1619, 1997.
